Stock XOMA XOMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News XOMA Corporation

Equities

XOMA

US98419J2069

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-03 EDT 		5-day change 1st Jan Change
24.78 USD -2.59% Intraday chart for XOMA Corporation -2.48% +33.95%
04-30 XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million. CI
04-29 Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
AQ
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.
CI
Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target
MT
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
AQ
XOMA : Acquisition/Asset Disposal - Form 8-K
PU
XOMA Corporation Announces Closing of Tender Offer
AQ
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..
CI
XOMA Declares Quarterly Preferred Stock Dividends
AQ
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
AQ
Xoma: Q4 Earnings Snapshot
AQ
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
AQ
XOMA to Present at Upcoming Investor Conferences in March
AQ
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right
AQ
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA
PR
Sector Update: Health Care Stocks Advance Friday Afternoon
MT
XOMA Agrees to Acquire Kinnate Biopharma
MT
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
AQ
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.
CI
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. News XOMA Corporation